4.3 Article

Long-Term Effectiveness and Safety of Childhood Growth Hormone Treatment in Noonan Syndrome

Journal

HORMONE RESEARCH IN PAEDIATRICS
Volume 93, Issue 6, Pages 380-395

Publisher

KARGER
DOI: 10.1159/000512429

Keywords

Noonan syndrome; Growth hormone therapy; Effectiveness; Safety; Near-adult height; RASopathy; Puberty; Real-world evidence; Adolescent; Ras; mitogen-activated protein kinase

Funding

  1. Novo Nordisk A/S

Ask authors/readers for more resources

This study evaluated the effectiveness and safety of GH treatment in patients with NS, finding significant height gain in patients over 3 years, with 24 patients achieving near-adult height, the majority with a height standard deviation score above -2. The occurrence of adverse drug reactions and serious events was relatively low.
Introduction: Few data exist on long-term growth hormone (GH) treatment in patients with Noonan syndrome (NS). Objective: To evaluate the effectiveness and safety of GH treatment in NS in clinical practice. Methods: Height gain, near-adult height (NAH), and safety were assessed in 2 complementary non-interventional studies: NordiNet (R) IOS and ANSWER. The safety analysis included 412 patients, and the effectiveness analysis included 84 GH-treated patients (male, n = 67) with >= 4 years' height standard deviation score (HSDS) data. HSDS was determined using national reference (NR) and NS-specific (NSS) data. Results: The mean (SD) baseline age was 8.38 (3.57) years; HSDS, -2.76 (1.03); GH dose, 41.6 (11.1) mu g/kg/day. The mean (SD) HSDS increase from baseline (Delta HSDS) was 0.49 (0.37) (first year), 0.79 (0.58) (second year), and 1.01 (0.60) (third year) (NR). The mean (SD) HSDS at year 3 was -1.66 (1.00) (NR; 1.06 [1.12] [NSS]). Twenty-four patients achieved NAH. The mean (SD) NAH SDS (NR) was -1.51 (0.60) (154.90 [3.21] cm) in females and -1.79 (1.09) (165.61 [7.19] cm) in males; 70.8% (17/24) had NAH SDS >= -2. Adverse drug reactions and GH-unrelated serious adverse events (n = 34) were reported in 22/412 (5.3%) patients. Four neoplasms and 3 cases of scoliosis were reported; no cardiovascular adverse events occurred. Conclusions: GH-treated children with NS achieved substantial height gain during the first 3 years of follow-up. Overall, 24 patients achieved NAH, with 70.8% having NAH SDS >= -2. There was no evidence to support a higher prevalence of neoplasm, or cardiac or other comorbidities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available